Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
Date:8/8/2011

THE WOODLANDS, Texas, Aug. 8, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.  

Progress in Clinical Pipeline

  • Lexicon commenced a Phase 2b clinical trial for LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2.  The company also presented data at the 71st Scientific Sessions of the American Diabetes Association from a mechanistic study designed to investigate the effect of LX4211 on peptide hormones in the intestinal tract in patients with type 2 diabetes.  The data from the study demonstrated that a single dose of LX4211 significantly increased GLP-1 (total and active) and PYY, important mediators of glycemic and appetite control.  
  • Lexicon successfully completed a Phase 1 study of LX1033, a serotonin synthesis inhibitor being developed as a potential treatment for irritable bowel syndrome (IBS).  Results from the study demonstrated that LX1033 was well tolerated at all doses and produced a statistically significant reduction in serotonin synthesis compared to placebo, as measured by both plasma (p<0.001) and urinary (p<0.01) 5-hydroxyindoleacetic acid (5-HIAA), a biomarker for serotonin synthesis.  Importantly, a greater reduction in serotonin synthesis was achieved with lower and less frequent dosing than was observed with Lexicon's first generation serotonin synthesis inhibitor, LX1031, which had previously demonstrated improvements in global assessment of adequate relief and
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
    2. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
    3. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
    4. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
    5. Lexicon to Provide First Quarter 2011 Financial Results
    6. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
    7. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
    9. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
    10. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
    11. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/21/2015)... CORAL SPRINGS, Florida , April 21, 2015 /PRNewswire/ ... in the U.S. are expected to grow at a ... for companies & vendors that provide technology services for ... Companies in focus today are: Surna Inc. (OTC: SRNA), ... (OTC: MJNA), Breathe, E-Cigs Corp. (OTC: BVAP), 22 nd ...
    (Date:4/21/2015)... , April 21, 2015  Decision Diagnostics ... administrator and the exclusive worldwide sales, service and ... the FDA-cleared Green Alternative Strip, specifically designed to ... LifeScan OneTouch Ultra family of glucose testing meters, ... announced today that Johnson & Johnson/Lifescan has requested ...
    (Date:4/21/2015)... , April 21, 2015  Navitas has launched ... a wide range of offerings for life sciences clients. ... an integrated platform enabling seamless flow of data across ... the Aviator launch, Navitas worked closely with Oracle to ... and Oracle,s CTMS in the Cloud. ...
    Breaking Medicine Technology:New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 2New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 3New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 4New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 5New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 6New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 7Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case 2Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 2Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 4
    (Date:4/21/2015)... Los Angeles, CA (PRWEB) April 21, 2015 ... Instead, it opened its doors today in the leafy, ... with a refreshed look and a new theme of “Disconnect ... the new owner of the award-winning day spa, announces ... in time for special Mother’s Day offerings that help celebrate ...
    (Date:4/21/2015)... Utah (PRWEB) April 21, 2015 Zane ... businesses, announced today its CEO Rick Lindquist has been ... for 2015. , According to Rick Lindquist, “There is ... industry, and Zane Benefits’ small business solutions are at ... recognition provided by Employee Benefit Adviser’s Rising Stars.” , ...
    (Date:4/21/2015)... has released a new blog post explaining the importance of ... on a uto insurance prices . , Drivers ... for advantageous auto insurance discounts. Clients can now review multiple ... will also help them get the best rates in their ... cost coverage is no longer difficult as there are multiple ...
    (Date:4/21/2015)... Optimity Advisors ( Optimity), ... that helps clients in complex industries navigate rapid ... Association of Community Affiliated Plans (ACAP) ... 58 local, not-for-profit, community-affiliated Safety Net Health Plans ... primarily enrolled in public or state-sponsored coverage programs, ...
    (Date:4/21/2015)... Quark Software Inc. has introduced ... solution that enables large enterprises to streamline the ... With Quark Procedure Management, corporate writers and subject ... to save, search and update, which is critical ... issues. Examples of policies and procedures include employee ...
    Breaking Medicine News(10 mins):Health News:Larchmont Sanctuary Spa Revealed as New Name For Neighborhood Spa; New Owner, New Eco Offerings & New Theme: “Disconnect to Reconnect” 2Health News:Larchmont Sanctuary Spa Revealed as New Name For Neighborhood Spa; New Owner, New Eco Offerings & New Theme: “Disconnect to Reconnect” 3Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Auto Insurance Quotes Offer Excellent Security for A Car 2Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 3
    ... By Jenifer Goodwin HealthDay Reporter , THURSDAY, ... falling behind on your mortgage payments hurts more than just ... with the struggle can also harm your physical and psychological ... on nearly 2,500 Americans who took part in the Health ...
    ... News) -- Most Americans consume too much sodium, and new ... of dietary salt, according to a new study by federal ... with increased risk of high blood pressure, which can lead ... people aged 2 years and older should limit daily sodium ...
    ... University of Houston (UH) are recommending a new strategy for ... diseases. In an invited review published in the ... at the Center for Nuclear Receptors and Cell Signaling (CNRCS) ... the team,s 1996 discovery of the estrogen receptor beta (ERβ). ...
    ... 20 (HealthDay News) -- There,s a suicide every 15 minutes in ... her own life there are many more who think about, plan ... The analysis of 2008-09 data from the National Survey on Drug ... range from about 1 in 50 adults in Georgia (2.1 percent) ...
    ... HOUSTON -- (Oct. 20, 2011) -- Bioengineers from Rice University ... a new "law of biology" can predict when a critically ... treatment is likely to prevent it. "We want to ... the principal investigator on a new $1.5 million grant from ...
    ... announce findings published in the October 20 issue of ... the inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with ... cause a sustained increase in high density lipoprotein cholesterol ... in the last decade has opened new insights for ...
    Cached Medicine News:Health News:Foreclosure Crisis Threatening Americans' Health: Study 2Health News:Foreclosure Crisis Threatening Americans' Health: Study 3Health News:U.S. Diet Still Has Too Much Salt, CDC Warns 2Health News:New drug strategies for Alzheimer's, multiple sclerosis examined at UH 2Health News:Suicide Rates Vary by Region: CDC 2Health News:Cloudy with a chance of sudden death 2Health News:Cloudy with a chance of sudden death 3Health News:Novel therapeutic target identified to decrease triglycerides and increase 'good' cholesterol 2
    Used to remove wrinkles from sections and for reorientating embedded tissue....
    ... CO-Oximeter Control (Bayer 800 Series) is ... monitoring the performance of blood gas, ... 270 and 800 series) instrumentation. This ... Bayer 800 Rapidlab Series instruments in ...
    Prevents formation of microscopic ice crystals and sample distortion caused by slow freezing of hyperosmolar tissue samples in conventional cyrostats....
    Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
    Medicine Products: